Form 8-K - Current report:
SEC Accession No. 0001437749-23-033343
Filing Date
2023-12-01
Accepted
2023-12-01 11:49:54
Documents
18
Period of Report
2023-11-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20231130_8k.htm   iXBRL 8-K 40373
2 EXHIBIT 10.1 ex_601957.htm EX-10.1 50199
3 EXHIBIT 10.2 ex_601958.htm EX-10.2 25545
4 EXHIBIT 10.3 ex_601959.htm EX-10.3 16738
5 EXHIBIT 10.4 ex_601960.htm EX-10.4 14795
6 EXHIBIT 99.1 ex_602049.htm EX-99.1 14699
  Complete submission text file 0001437749-23-033343.txt   328420

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA navb-20231127.xsd EX-101.SCH 3409
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20231127_def.xml EX-101.DEF 11056
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20231127_lab.xml EX-101.LAB 14798
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20231127_pre.xml EX-101.PRE 11161
12 EXTRACTED XBRL INSTANCE DOCUMENT navb20231130_8k_htm.xml XML 2485
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 231458154
SIC: 2835 In Vitro & In Vivo Diagnostic Substances